Welcome to our dedicated page for Salarius Pharmaceuticals news (Ticker: SLRX), a resource for investors and traders seeking the latest updates and insights on Salarius Pharmaceuticals stock.
The news feed for Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) captures the company’s transition as it integrates Decoy Therapeutics and pivots toward a peptide-conjugate antiviral and oncology platform. Press releases and regulatory announcements describe how Salarius, historically a clinical-stage biopharmaceutical company with oncology assets, completed a strategic merger with Decoy and is preparing to operate under the Decoy Therapeutics name and the Nasdaq ticker symbol DCOY.
Readers following SLRX news can expect updates on corporate transformation, including the planned and then confirmed changes to the corporate name and trading symbol, as well as details of the merger structure, preferred stock issuance and leadership changes documented in company communications and SEC filings. The news flow also highlights capital markets activity, such as underwritten public offerings of common stock and warrants, at-the-market issuances and efforts to regain and maintain compliance with Nasdaq listing standards, including reverse stock splits and panel monitoring.
Sector-specific coverage focuses on drug development and platform progress. Company announcements describe the IMP3ACT peptide-conjugate platform, pan‑coronavirus and broad-acting antiviral programs, and a peptide drug conjugate targeting GI cancers. News items also cover collaborations, notably with Texas Biomedical Research Institute for in vitro testing of peptide conjugate fusion inhibitors across influenza strains including H5N1 avian flu, and recognition from programs such as the Massachusetts Life Sciences Seed Fund, the Google AI startup program, the NVIDIA Inception program and BARDA’s BLUE KNIGHT initiative.
By monitoring this page, investors and observers can review historical and ongoing disclosures around SLRX’s oncology heritage, its integration with Decoy’s AI- and ML-enabled peptide-conjugate platform, financing transactions and interactions with the Nasdaq Capital Market, all drawn from company-issued news and related filings.
Salarius Pharmaceuticals (NASDAQ:SLRX) will change its corporate name to Decoy Therapeutics and begin trading under the ticker DCOY on January 8, 2026.
The company says its proprietary AI-enabled peptide-conjugate platform targets pan-coronavirus and multi-viral threats, with a lead antiviral program of interest to BARDA and global health organizations. Decoy describes a capital-efficient 2026 plan to advance its lead antiviral toward the clinic, expand discovery and pursue IND filings, partnerships and non-dilutive funding while retaining current share structure and leadership.
Salarius Pharmaceuticals (Nasdaq: SLRX) adjourned its 2025 Annual Meeting held on Dec 19, 2025 because fewer than the required 34% quorum of outstanding shares were represented in person or by proxy.
The meeting will be reconvened on Dec 31, 2025 at 10:00 a.m. CT as a virtual webcast at www.virtualshareholdermeeting.com/SLRX2025. The record date remains Oct 24, 2025. At adjournment, proxies represented approximately 30% of outstanding shares.
Stockholders as of the record date are urged to vote via www.proxyvote.com, phone at 1-800-690-6903, or by contacting proxy solicitor Alliance Advisors at SLRX@allianceadvisors.com. Proxy materials are available free at sec.gov and the company investor site.
Salarius Pharmaceuticals (NASDAQ: SLRX) announced that following its combination with Decoy Therapeutics, it will change its corporate name to Decoy Therapeutics, Inc. and adopt the NASDAQ ticker DCOY, expected to become effective in early January 2026. The company will continue trading as SLRX until the effective date and the transfer agent remains unchanged. Decoy management, joined by Salarius finance, will lead operations as the combined business focuses on a peptide-conjugate platform targeting viral diseases and oncology.
Key priorities for 2026 include advancing lead antiviral programs toward regulatory readiness, expanding preclinical validation, leveraging AI-enabled discovery, and pursuing collaborations and non-dilutive funding.
Salarius Pharmaceuticals (Nasdaq: SLRX) announced a collaboration with Texas Biomedical Research Institute on Decoy Therapeutics’ peptide conjugate influenza fusion inhibitors, including testing across several influenza strains such as H5N1 avian flu (Dec. 1, 2025). The company says its IMP3ACT™ platform produced inhibitors with strong in silico free energy binding to the viral entry protein and seeks in vitro confirmation at Texas Biomed.
Salarius completed a merger with Decoy and an underwritten public offering raising $8 million on Nov. 13, 2025, and expects to file an IND for a pan-coronavirus lead asset within 12 months.
Salarius Pharmaceuticals (Nasdaq: SLRX) confirmed that its common stock continues to trade on the Nasdaq under the ticker SLRX after identifying inaccurate delisting information on the S&P CapIQ platform.
On Nov 13, 2025 the company completed an underwritten public offering raising gross proceeds of $8 million and closed its merger with Decoy Therapeutics; the combined company reports pro forma cash of approximately $14 million and about 5.9 million shares outstanding.
Salarius said it is advancing Decoy’s peptide conjugate pipeline and expects to pursue an IND filing within 12 months for a pan-coronavirus antiviral.
Salarius Pharmaceuticals (Nasdaq: SLRX) and Decoy Therapeutics completed a strategic merger on November 13, 2025, creating a combined company to be renamed Decoy Therapeutics.
The combined business will advance Decoy’s IMP3ACT™ platform that uses AI/ML and high-speed synthesis to design and manufacture peptide conjugate therapeutics. The merger yields pro forma cash of $14 million following the closing and a recent public offering. Management will be led by Decoy founders including CEO Frederick Pierce and CSO Barbara Hibner, with Mark Rosenblum remaining CFO.
The company expects to advance its lead pan-coronavirus antiviral to an IND filing within 12 months and progress programs for broad-acting respiratory antivirals and a peptide drug conjugate for GI cancers.
Salarius Pharmaceuticals (NASDAQ: SLRX) priced an underwritten public offering to raise approximately $7.0 million of gross proceeds through the sale of 2,514,335 common shares and pre-funded warrants for 2,152,331 shares, each accompanied by Series A and Series B warrants covering up to a combined 4,666,666 shares per warrant series. The combined public price is $1.50 per share with warrants and $1.4999 per pre-funded warrant with warrants.
The offering includes a 45-day underwriter option for up to 699,999 additional units, is managed by Ladenburg Thalmann, and is expected to close on or about November 12, 2025, subject to closing conditions including completion of the proposed business combination with Decoy Therapeutics. Net proceeds are expected to fund clinical development, repay certain Decoy promissory notes, and support general corporate purposes.
Salarius Pharmaceuticals (Nasdaq: SLRX) announced it regained compliance with Nasdaq Listing Rule 5550(b)(1) on October 10, 2025, completing compliance with all Nasdaq listing requirements after earlier regaining the Minimum Bid Price rule on September 9, 2025.
The company reiterated its planned business combination with Decoy Therapeutics, originally announced in a definitive merger agreement dated January 13, 2025; under the agreement Decoy will merge with a Salarius subsidiary and the combined company will be named Decoy Therapeutics.
Nasdaq also notified Salarius it will be subject to a Mandatory Panel Monitor for one year from October 10, 2025, and that a renewed breach during that period could trigger a delisting determination with a hearing opportunity.
Salarius Pharmaceuticals (Nasdaq: SLRX) has regained compliance with Nasdaq's Minimum Bid Price Requirement (Rule 5550(a)(2)) as of September 4, 2025. The company still needs to meet the Equity Standard Requirement (Rule 5550(b)(1)) by October 20, 2025 to maintain its listing.
SLRX will be under a Mandatory Panel Monitor for one year starting September 4, 2025. Additionally, the company has previously announced a definitive merger agreement with Decoy Therapeutics on January 13, 2025. Post-merger, the combined entity will operate as Decoy Therapeutics, focusing on developing peptide conjugate therapeutics.
Salarius Pharmaceuticals (NASDAQ: SLRX), a clinical-stage biopharmaceutical company, has announced a 1-for-15 reverse stock split effective August 15, 2025. The split aims to regain compliance with Nasdaq's minimum $1.00 bid price requirement.
Following the split, SLRX's outstanding shares will reduce from approximately 7.6 million to 509,000 shares. Trading on a split-adjusted basis will begin August 18, 2025, under a new CUSIP number 79400X503. The split will uniformly affect all stockholders, with cash provided for fractional shares based on the August 15 closing price.
The reverse split was approved by stockholders on July 8, 2025, and will adjust all outstanding options, warrants, and shares reserved under the 2015 Employee Stock Purchase Plan accordingly.